MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.14
-0.28
-2.97%
Opening 14:34 07/09 EDT
OPEN
9.45
PREV CLOSE
9.42
HIGH
9.76
LOW
9.08
VOLUME
3.74M
TURNOVER
--
52 WEEK HIGH
9.76
52 WEEK LOW
1.800
MARKET CAP
928.62M
P/E (TTM)
-5.2829
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DVAX stock price target is 15.33 with a high estimate of 20.00 and a low estimate of 12.00.

EPS

DVAX News

More
Moderna completes enrollment in mid-stage study of COVID-19 vaccine
In a post on social media, Moderna (MRNA +2.0%) announces that it has completed enrollment in a Phase 2 clinical trial evaluating the safety, reactogenicit
seekingalpha · 23h ago
Dynavax teams up with Medicago to develop COVID-19 vaccine
Dynavax (NASDAQ:DVAX) will partner with Medicago to develop a COVID-19 vaccine that combines the latter's Coronavirus Virus-Like Particle and its CpG 1018
seekingalpha · 1d ago
If You Had Bought Dynavax Technologies (NASDAQ:DVAX) Shares A Year Ago You'd Have Earned133% Returns
Simply Wall St. · 1d ago
Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?
Zacks · 2d ago
4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine
Zacks · 2d ago
Is Dynavax Technologies Stock a Buy?
MotleyFool.com · 4d ago
Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today
MotleyFool.com · 07/01 19:56
Smaller cap COVID-19 vaccine players under pressure on Pfizer data
Seeking Alpha - Article · 07/01 15:32

Industry

Biotechnology & Medical Research
-0.28%
Pharmaceuticals & Medical Research
-0.70%

Hot Stocks

Symbol
Price
%Change

About DVAX

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
More

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.